Seroepidemiology of hepatitis C virus infection in people aged 1–69 years in China: a national, cross-sectional study

作者：Jian Li, Lin Pang, Guowei Ding, Wenge Xing, Jiejun Yu, Hui Zheng, Yu Wang, Fuzhen Wang, Liping Shen, Jianhua Liu, Shaodong Ye, Lijian Pei, Feng Wang, Guomin Zhang, Ning Miao, Tongtong Meng, Zundong Yin, Jidong Jia, Jun Yan, Yu Wang, Zhongfu Liu · 发表于：The Lancet Public Health · 年份：2025 · DOI：10.1016/s2468-2667(25)00254-3 · 被引用次数：3 · 研究领域：Hepatitis C virus research、Hepatitis B Virus Studies、Hepatitis Viruses Studies and Epidemiology

BACKGROUND: China has a substantial disease burden of hepatitis C virus (HCV) infection. We aimed to analyse the findings from a national seroepidemiology survey of viral hepatitis in 2020, providing insights into the current state of hepatitis C in China. METHODS: A national, cross-sectional survey was conducted in China using a stratified, three-stage cluster random sampling method to select individuals aged 1-69 years from 160 national disease surveillance points. Venous blood samples that tested positive for anti-HCV antibodies were further tested for HCV RNA. Point estimates and 95% CIs of anti-HCV antibody and HCV RNA prevalence were calculated using Taylor series linearisation for variance estimations. The prevalence estimates were adjusted using weighted calculations. National HCV burden was estimated by the workbook method. FINDINGS: From Aug 1, 2020, to June 1, 2021, 91 971 individuals were surveyed in 120 counties, with 91 896 (99·9%) blood samples tested and included in the final analysis. The median age of participants was 33 years (IQR 15-52), 39 627 (43·1%) participants were male, 52 269 (56·9%) were female, 75 170 (81·8%) were of Han ethnicity, and 16 726 (18·2%) were in non-Han ethnic groups. 223 (0·24%) individuals tested positive for anti-HCV antibodies, with weighted prevalence of 0·28% (95% CI 0·24-0·34). Among these, 111 (49·8%) tested positive for HCV RNA, resulting in an HCV RNA positive proportion of 0·12% and weighted prevalence of 0·15% (95% CI 0·11...